¹Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio
²Neurologic Institute, Respiratory Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio
³Department of Infectious Diseases, Cleveland Clinic Florida, Weston

Read article on JAMA Network

Read Article Claim CME

Key Points

Question Do high-dose zinc, high-dose ascorbic acid, and/or a combination of the 2 reduce the duration of symptoms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)?

Findings In this randomized clinical trial of 214 patients with confirmed SARS-CoV-2 infection receiving outpatient care, there was no significant difference in the duration of symptoms among the 4 groups.

Meaning These findings suggest that treatment with zinc, ascorbic acid, or both does not affect SARS-CoV-2 symptoms.

Abstract

Importance There is limited evidence regarding early treatment of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection to mitigate symptom progression.

Objective To examine whether high-dose zinc and/or high-dose ascorbic acid reduce the severity or duration of symptoms compared with usual care among ambulatory patients with SARS-CoV-2 infection.

Design, Setting, and Participants This multicenter, single health system randomized clinical factorial open-label trial enrolled 214 adult patients with a diagnosis of SARS-CoV-2 infection confirmed with a polymerase chain reaction assay who received outpatient care in sites in Ohio and Florida. The trial was conducted from April 27, 2020, to October 14, 2020.

Intervention Patients were randomized in a 1:1:1:1 allocation ratio to receive either 10 days of zinc gluconate (50 mg), ascorbic acid (8000 mg), both agents, or standard of care.

Outcomes The primary end point was the number of days required to reach a 50% reduction in symptoms, including severity of fever, cough, shortness of breath, and fatigue (rated on a 4-point scale for each symptom). Secondary end points included days required to reach a total symptom severity score of 0, cumulative severity score at day 5, hospitalizations, deaths, adjunctive prescribed medications, and adverse effects of the study supplements.

Results A total of 214 patients were randomized, with a mean (SD) age of 45.2 (14.6) years and 132 (61.7%) women. The study was stopped for a low conditional power for benefit with no significant difference among the 4 groups for the primary end point. Patients who received usual care without supplementation achieved a 50% reduction in symptoms at a mean (SD) of 6.7 (4.4) days compared with 5.5 (3.7) days for the ascorbic acid group, 5.9 (4.9) days for the zinc gluconate group, and 5.5 (3.4) days for the group receiving both (overall P = .45). There was no significant difference in secondary outcomes among the treatment groups.

Conclusions and Relevance In this randomized clinical trial of ambulatory patients diagnosed with SARS-CoV-2 infection, treatment with high-dose zinc gluconate, ascorbic acid, or a combination of the 2 supplements did not significantly decrease the duration of symptoms compared with standard of care.

Trial Registration ClinicalTrials.gov Identifier: NCT04342728

Claim CME

Buy This Activity

Article Information

Accepted for Publication: January 9, 2021.

Published: February 12, 2021. doi:10.1001/jamanetworkopen.2021.0369

Corresponding Author: Milind Y. Desai, MD, MBA, Heart and Vascular Institute, Cleveland Clinic, 9500 Euclid Ave, Desk J1-5, Cleveland, OH 44195 (desaim2@ccf.org).

Author Contributions: Dr Desai had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Thomas, Patel, Bittel, Kumar, Mehra, McWilliams, Nissen, Desai.

Acquisition, analysis, or interpretation of data: Thomas, Patel, Bittel, Wolski, Wang, Kumar, Il’Giovine, Mehra, Nissen, Desai.

Drafting of the manuscript: Thomas, Patel, Bittel, Kumar, Il’Giovine, Mehra, Desai.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Wolski, Wang, Kumar, Desai.

Obtained funding: Thomas, Kumar, Desai.

Administrative, technical, or material support: Thomas, Bittel, Kumar, Nissen, Desai.

Supervision: Thomas, Bittel, Kumar, Il’Giovine, Nissen, Desai.

Conflict of Interest Disclosures: Dr McWilliams reported receiving consulting fees from Gilead Sciences outside the submitted work. Dr Desai reported receiving grants from Myokardia outside the submitted work and being supported by the Haslam Family Endowed Chair in Cardiovascular Medicine. No other disclosures were reported.

Additional Contributions: Serpil Erzurum, MD, James Young, MD, Daniel Culver, MD, Joan Booth, RN, Nancy Obuchowski, MPH, and John Petrich, RPh (Cleveland Clinic), were members of the operational and safety monitoring board. They were not compensated for their time. We would like to thank Samantha Xu, BS (Cleveland Clinic), for help with logistics of study set-up and coordination. She was compensated for her time.

References

Huang C , Wang Y , Li X , et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5 PubMed Google Scholar Crossref

US Centers for Disease Control and Prevention. COVID-19. Accessed January 12, 2021. https://www.cdc.gov/coronavirus/2019-ncov/index.html

Wu Z , McGoogan JM . Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-1242. doi:10.1001/jama.2020.2648 PubMed Google Scholar Crossref

Gammoh NZ , Rink L . Zinc in infection and inflammation. Nutrients. 2017;9(6):E624. doi:10.3390/nu9060624 PubMed Google Scholar

Hemilä H . Vitamin C and infections. Nutrients. 2017;9(4):E339. doi:10.3390/nu9040339 PubMed Google Scholar

Hemilä H , Chalker E . Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev. 2013;(1):CD000980. doi:10.1002/14651858.CD000980.pub4 PubMed Google Scholar

Singh M , Das RR . Zinc for the common cold. Cochrane Database Syst Rev. 2011;(2):CD001364. doi:10.1002/14651858.CD001364.pub3 PubMed Google Scholar

Eby GA , Davis DR , Halcomb WW . Reduction in duration of common colds by zinc gluconate lozenges in a double-blind study. Antimicrob Agents Chemother. 1984;25(1):20-24. doi:10.1128/AAC.25.1.20 PubMed Google Scholar Crossref

Hemilä H . Zinc lozenges and the common cold: a meta-analysis comparing zinc acetate and zinc gluconate, and the role of zinc dosage. JRSM Open. 2017;8(5):2054270417694291. doi:10.1177/2054270417694291 PubMed Google Scholar

10.

Carr AC . Vitamin C administration in the critically ill: a summary of recent meta-analyses. Crit Care. 2019;23(1):265. doi:10.1186/s13054-019-2538-y PubMed Google Scholar Crossref

11.

te Velthuis AJ , van den Worm SH , Sims AC , Baric RS , Snijder EJ , van Hemert MJ . Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. PLoS Pathog. 2010;6(11):e1001176. doi:10.1371/journal.ppat.1001176 PubMed Google Scholar

12.

Li W , Moore MJ , Vasilieva N , et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450-454. doi:10.1038/nature02145 PubMed Google Scholar Crossref

13.

Krenn BM , Gaudernak E , Holzer B , Lanke K , Van Kuppeveld FJ , Seipelt J . Antiviral activity of the zinc ionophores pyrithione and hinokitiol against picornavirus infections. J Virol. 2009;83(1):58-64. doi:10.1128/JVI.01543-08 PubMed Google Scholar Crossref

14.

Hemilä H . Vitamin C, respiratory infections and the immune system. Trends Immunol. 2003;24(11):579-580. doi:10.1016/j.it.2003.09.004 PubMed Google Scholar Crossref

15.

Davelaar FG , Bos J . Ascorbic acid and infectious bronchitis infections in broilers. Avian Pathol. 1992;21(4):581-589. doi:10.1080/03079459208418879 PubMed Google Scholar Crossref

16.

Weismann K , Jakobsen JP , Weismann JE , et al. Zinc gluconate lozenges for common cold: a double-blind clinical trial. Dan Med Bull. 1990;37(3):279-281.PubMed Google Scholar

17.

Meltzer DO , Best TJ , Zhang H , Vokes T , Arora V , Solway J . Association of vitamin D status and other clinical characteristics with COVID-19 test results. JAMA Netw Open. 2020;3(9):e2019722. doi:10.1001/jamanetworkopen.2020.19722 PubMed Google Scholar

Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 InfectionThe COVID A to Z Randomized Clinical Trial

Supplements for the Treatment of Mild COVID-19

See More About

If you are not a JN Learning subscriber, you can either:

A subscription to JN Learning (CME from JAMA Network) provides:

Sign in to access

If you are not a JN Learning subscriber, you can either:

Sign in to customize your interests

With a personal account, you can:

Name Your Search

Sign in to save your search

With a personal account, you can:

Lookup An Activity

My Saved Searches

Sign in to customize your interests

With a personal account, you can:

Purchase access